65,437 trials
Healthy
Primary: Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium — 67.258; 60.552 Nanogram per milliliter (ng/mL)
Tooth Wear
Primary: Basic Erosive Wear Examination — 15.01; 6.27 Units on a scale — p=<0.05
Major Depressive Disorder
Primary: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. — -13.19; -9.21; -9.2; -13.4 score on a…
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — -16.9; -2.3; 0.2; -17.0 percent change
HIV/AIDS
Primary: Retention in Care — 80; 79 percentage of medication coverage
Problematic AOD Use
Primary: Drug Use Disorders Identification Test-Consumption (DUDIT-C) — 4.8; 4.5 units on a scale
HIV Infections · Sexually Transmitted Diseases
Primary: Acceptability — 88; 83 Participants
Postpartum Contraception · Family Planning
Primary: Time to Lactogenesis Stage II [Questionnaire] — 65; 67.5 hours
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Renal Failure
Primary: Feasibility of Participant Recruitment and Site Coordination — 8; 6 Participants
Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Overall Survival (OS) — 5.4; 6.5 months — p=0.28
Nephropathy · Sickle Cell Anemia
Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants
Pain
Primary: Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade - — 0.3635; 0.7358; 0.0887; -0.1983 Degrees Centigrade
Borderline Ovarian Serous Tumor · Micropapillary Serous Carcinoma · Ovarian Serous Adenocarcinoma
Primary: Progression-free Survival (PFS) — 7.2; 13.0 months
Cystic Fibrosis
Primary: Sweat Chloride Concentration — NA mmol/L